Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Trimmed by Schroder Investment Management Group

Schroder Investment Management Group reduced its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 50.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 23,230 shares of the biopharmaceutical company’s stock after selling 24,112 shares during the quarter. Schroder Investment Management Group’s holdings in Alnylam Pharmaceuticals were worth $5,483,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. boosted its stake in Alnylam Pharmaceuticals by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company’s stock valued at $2,996,296,000 after acquiring an additional 98,303 shares during the period. Regeneron Pharmaceuticals Inc. acquired a new position in Alnylam Pharmaceuticals during the 4th quarter valued at approximately $1,045,822,000. Norges Bank bought a new position in Alnylam Pharmaceuticals during the 4th quarter worth $577,941,000. Geode Capital Management LLC increased its position in Alnylam Pharmaceuticals by 3.2% in the third quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock worth $589,209,000 after buying an additional 66,928 shares during the period. Finally, American Century Companies Inc. lifted its stake in Alnylam Pharmaceuticals by 0.7% in the fourth quarter. American Century Companies Inc. now owns 1,604,024 shares of the biopharmaceutical company’s stock valued at $377,443,000 after buying an additional 11,291 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 10.1 %

Shares of Alnylam Pharmaceuticals stock opened at $235.74 on Friday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The firm has a market capitalization of $30.67 billion, a PE ratio of -108.64 and a beta of 0.30. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The stock’s fifty day moving average is $259.03 and its 200-day moving average is $260.33.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

ALNY has been the subject of several recent research reports. Citigroup upped their price target on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a “buy” rating in a research report on Friday, March 21st. Chardan Capital restated a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. JPMorgan Chase & Co. raised Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $280.00 to $328.00 in a report on Monday, March 24th. Stifel Nicolaus increased their price objective on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a “buy” rating in a report on Monday, March 31st. Finally, Wells Fargo & Company lifted their target price on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an “equal weight” rating in a research note on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $316.25.

Insider Activity at Alnylam Pharmaceuticals

In other news, Director Phillip A. Sharp sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Jeffrey V. Poulton sold 967 shares of the stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the sale, the chief financial officer now directly owns 32,786 shares of the company’s stock, valued at approximately $8,366,003.62. This represents a 2.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.